PSE boosts PSA accuracy from 55% to 94% for confirming the presence or absence of prostate cancer. The highly accurate blood test is simple to order by a physician and is available to men in the US and UK under the immediate access program.
An effective screening test that identifies an individual’s current risk of prostate cancer from blood. PSE is administered alongside or following a standard PSA test to significantly boost screening performance and reduce the number of men referred for unnecessary biopsies and treatments.
This powerful test is valuable for identifying individuals requiring biopsy and those suitable for active surveillance without further testing.
Learn more about EpiSwitch PSE
A first-of-its-kind blood test to provide guidance on navigating the toughest challenges associated with use of an essential, widely-used class of cancer therapies: Immune Checkpoint Inhibitors.
Now every patient can benefit from the world’s first test to assess the probability of therapeutic success of checkpoint inhibitor therapy with high accuracy.
Learn More about EpiSwitch CiRT